IN8bio, Inc.

NASDAQ (USD): IN8bio, Inc. (INAB)

Last Price

2.25

Today's Change

+0.028 (1.25%)

Day's Change

2.20 - 2.27

Trading Volume

41,579

Overview

Market Cap

7 Million

Shares Outstanding

3 Million

Avg Volume

154,592

Avg Price (50 Days)

4.16

Avg Price (200 Days)

7.31

PE Ratio

-0.17

EPS

-13.20

Earnings Announcement

07-Aug-2025

Previous Close

2.23

Open

2.25

Day's Range

2.205 - 2.27

Year Range

2.06 - 27.6

Trading Volume

41,579

Price Change Highlight

1 Day Change

1.27%

5 Day Change

5.04%

1 Month Change

-48.08%

3 Month Change

-66.98%

6 Month Change

-67.92%

Ytd Change

-73.15%

1 Year Change

-91.46%

3 Year Change

-96.90%

5 Year Change

-99.25%

10 Year Change

-99.25%

Max Change

-99.25%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment